Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neuroprotectin D1 + resolvin D1
- Development stage
- Preclinical
- Lead developer
- Louisiana State University Health Sciences Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Neuroprotectin D1 (NPD1) + Resolvin D1 (RvD1) is a combination therapy composed of two specialized pro-resolving mediators (SPMs) derived from docosahexaenoic acid (DHA). This docosanoid combination is being investigated for the treatment of acute ischemic stroke, where it acts to resolve neuroinflammation and promote tissue repair. The mechanism involves the activation of specific G protein-coupled receptors (such as FPR2/ALX, GPR32, and GPR37) to antagonize pro-inflammatory signaling, reduce leukocyte infiltration, and enhance the clearance of apoptotic cells by macrophages. Preclinical studies in rat models of middle cerebral artery occlusion (MCAo) have demonstrated that the combination significantly reduces cortical and subcortical lesion volumes and provides sustained neurobehavioral recovery when administered within a 6-hour therapeutic window. The therapy also modulates the expression of homeostatic microglial and astrocyte genes to restore brain homeostasis after injury.
- Other names
- NPD1 + RvD1Protectin D1 + Resolvin D1
02
Targets
GPR37 (G protein-coupled receptor 37)GPR32 (G protein-coupled receptor 32)
Beyond the preview
Go deeper on neuroprotectin D1 + resolvin D1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neuroprotectin D1 + resolvin D1.